Literature DB >> 9333029

Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection.

H Mattie1, L C Zhang, E van Strijen, B R Sekh, A E Douwes-Idema.   

Abstract

The efficacies of meropenem (MPM) and cloxacillin (CLC) against two Staphylococcus aureus strains were established in vitro. A pharmacodynamic model equation, based on the concept that the killing rate depends on concentration and time, was fitted to the numbers of CFU. The parameters of the equation are maximum killing rate, time point of maximum killing, and 50% effective concentration (EC50). The EC50s for the two strains were 0.047 and 0.040 mg/liter, respectively, for MPM and 0.105 and 0.121 mg/liter, respectively, for CLC. Calculated values of the parameters were used to predict the numbers of CFU at exponentially decreasing concentrations in vitro as well as in an experimental infection model. The prediction for in vitro conditions gave a satisfactory fit (R2, between 0.862 and 0.894). In vivo the numbers were predicted with the assumption that killing rate in vivo is proportional to that in vitro (R2, between 0.731 and 0.973). The proportionality factor ranged between 0.23 and 0.42; this variation was due mainly to covariation with growth rates in control animals, without other significant differences between antibiotics or strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333029      PMCID: PMC164074     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

Authors:  W E Peetermans; J J Hoogeterp; A M Hazekamp-van Dokkum; P van den Broek; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

2.  Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.

Authors:  H Mattie; A M van Dokkum; L Brus-Weijer; A M Krul; E van Strijen
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  Effectiveness of netilmicin and tobramycin against Pseudomonas aeruginosa in vitro and in an experimental tissue infection in mice.

Authors:  B G Moffie; J J Hoogeterp; T Lim; A E Douwes-Idema; H Mattie
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

5.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Authors:  E Tuomanen; R Cozens; W Tosch; O Zak; A Tomasz
Journal:  J Gen Microbiol       Date:  1986-05

6.  Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.

Authors:  H Mattie; B A Sekh; M L van Ogtrop; E van Strijen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

  6 in total
  12 in total

1.  Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

3.  Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.

Authors:  Kazuhiro Oshima; Shigeki Nakamura; Naoki Iwanaga; Koji Takemoto; Taiga Miyazaki; Kastunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno; Koichi Izumikawa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  The efficiency concept in pharmacodynamics.

Authors:  G Alván; G Paintaud; M Wakelkamp
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

6.  Activity of carbapenems combined with clavulanate against murine tuberculosis.

Authors:  Nicolas Veziris; Chantal Truffot; Jean-Luc Mainardi; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

7.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

9.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

10.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.